MedTrace Logo

Evaluating Immune Response to Seasonal FluMist in Healthy Adults

NCT01673425 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2021-01-27

Study results available
· View outcomes & findings →

Summary

The Live-Attenuated Influenza Vaccine (LAIV), also known as FluMist, has been shown to be effective in children but less effective in adults. Our hypothesis is that this relative failure is due to adults having enough anti-flu IgA antibody in nasal secretions to neutralize the weakened vaccine virus.

Conditions

Interventions

DRUG

Live Attenuated Influenza Vaccine

All participants will be given FluMist.

Sponsors & Collaborators

Principal Investigators

  • Lewis J. Radonovich, MD · National Center for Occupational Health and Infection Control

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
49 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2012-12-31
Completion
2012-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01673425 on ClinicalTrials.gov